Bio


Alex Lyapin is a Nurse Practitioner at Stanford Health Care with the Department of Heart Transplant and Mechanical Circulatory Support. He completed his MSN NP degree in 2015 at Western Carolina University and then DNP at Frontier Nursing University in 2018. He came to work at Stanford in 2016 initially to the Department of Vascular Surgery. Currently, Dr. Lyapin works in both inpatient and outpatient setting providing cardiology care to patients after heart transplant or left-ventricular assist device implant. He is actively involved in many teaching initiatives in his department such as annual Stanford MCS Symposium and ACES.

Clinical Focus


  • Nurse Practitioner
  • Cardiology
  • Heart Transplantation
  • Heart Failure

Professional Education


  • Bachelor of Science, Western Carolina University, Nursing (2011)
  • Master of Science, Western Carolina University, Family Nurse Practitioner (2015)
  • Doctor of Nursing Practice, Frontier Nursing University (2018)

All Publications


  • Ace in the Hole Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in the First Year after Heart Transplant Henricksen, E. J., Moayedi, Y., Lee, R., Han, J., Waddell, K., Luikart, H., Morales, D. P., Gordon, J., Lyapin, A., Duclos, S., Jimenez, S., Khush, K. K., Teuteberg, J. J. ELSEVIER SCIENCE INC. 2021: S284
  • Donor Drug Overdose Not Associated with Primary Graft Dysfunction after Heart Transplantation Han, J., Moayedi, Y., Henricksen, E. J., Lee, R., Waddell, K., Luikart, H. I., Morales, D. P., Gordon, J., Lyapin, A., Duclos, S., Feng, K. Y., Jimenez, S., Teuteberg, J. J., Khush, K. K. ELSEVIER SCIENCE INC. 2021: S286-S287
  • Don't Go Breakin' My Heart: Lack of Association between Granulocyte Colony Stimulating Factor and Development of Acute Cellular Rejection Lee, R., Henricksen, E. J., Moayedi, Y., Han, J., Feng, K. Y., Waddell, K., Luikart, H., Morales, D., Gordon, J., Lyapin, A., Duclos, S., Jimenez, S., Teuteberg, J. J., Khush, K. K. ELSEVIER SCIENCE INC. 2021: S285
  • Impact of using higher-risk donor hearts for candidates with pre-transplant mechanical circulatory support. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Han, J., Moayedi, Y., Yang, W., Henricksen, E. J., Lee, R., Purewal, S., Chang, E., Duclos, S., Lyapin, A., Feng, K., Hiesinger, W., Teuteberg, J. J., Khush, K. K. 2021

    Abstract

    We evaluated post-heart transplant (HTx) outcomes after use of higher-risk donor hearts for candidates supported with pre-HTx mechanical circulatory support (MCS).In this retrospective analysis of the national United Network for Organ Sharing registry, a total of 9,915 adult candidates on MCS underwent HTx from January 1, 2010 to March 31, 2019. Multi-organ, re-transplant, and congenital heart disease patients were excluded. Higher-risk donor organs met at least one of the following criteria: left ventricular ejection fraction <50%, donor to recipient predicted heart mass ratio <0.86, donor age >55 years, or ischemic time >4 hours. Primary outcome was 1 year post-transplant survival.Among HTx recipients, 3688 (37.2%) received higher-risk donor hearts. Candidates supported with pre-HTx extracorporeal membrane oxygenation or biventricular assist device (n = 374, 3.8%) who received higher-risk donor hearts had comparable 1 year survival (HR: 1.14, 95% CI: [0.67-1.93], p = 0.64) to recipients of standard-risk donor hearts, when adjusted for recipient age and sex. In candidates supported with intra-aortic balloon pump (n = 1391, 14.6%), transplantation of higher-risk donor hearts did not adversely affect 1 year survival (HR: 0.80, 95% CI: [0.52-1.22], p = 0.30). Patients on durable left ventricular assist devices (LVAD) who received higher-risk donor hearts had comparable 1 year survival to continued LVAD support on the waitlist, but mortality was increased compared to those who received standard-risk donor hearts (HR: 1.37, 95% CI: [1.11-1.70], p = 0.004).Patients requiring pre-HTx temporary MCS who received higher-risk donor hearts had comparable 1 year post-transplant survival to those who received standard-risk donor hearts. Stable patients on durable LVADs may benefit from waiting for standard-risk donor hearts.

    View details for DOI 10.1016/j.healun.2021.09.016

    View details for PubMedID 34815161

  • To SIPAT or Not to SIPAT: The Stanford Integrated Psychosocial Assessment for Transplant Moayedi, Y., Yang, W. A., Mueller, B., Fan, C. S., Purewal, S., Ramirez, N., Han, J., Henricksen, E. J., Lee, R., Duclos, S., Lyapin, A., Wainwright, R., Hiesinger, W., Ross, H. J., Khush, K. K., Teuteberg, J. J. ELSEVIER SCIENCE INC. 2020: S39–S40
  • Take the First Available Heart: Use of Higher-Risk Donors in Recipients with Pre-Transplant Mechanical Circulatory Support Han, J., Moayedi, Y., Yang, W., Henricksen, E. J., Lee, R., Purewal, S., Chang, E., Duclos, S., Lyapin, A., Feng, K. Y., Hiesinger, W., Teuteberg, J. J., Khush, K. K. ELSEVIER SCIENCE INC. 2020: S42
  • Severe Primary Graft Dysfunction: Impact of the New UNOS Heart Allocation System Han, J., Moayedi, Y., Yang, W., Henricksen, E. J., Lee, R., Purewal, S., Chang, E., Duclos, S., Lyapin, A., Tremblay-Gravel, M., Alexander, K. M., Kawana, M., Hiesinger, W., Teuteberg, J. J., Khush, K. K. ELSEVIER SCIENCE INC. 2020: S173–S174
  • Malignancy Following Heart Transplant: Few and Far Between Chang, E., Moayedi, Y., Hoppenfeld, M., Lafreniere-Roula, M., Fan, S., Henricksen, E. J., Feng, K., Morales, D. P., Purewal, S., Duclos, S., Lee, R., Lyapin, A., Currie, M., Ross, H. J., Teuteberg, J. J., Khush, K. K. ELSEVIER SCIENCE INC. 2020: S282–S283
  • Moving towards an Induction-Free Era: Short-Term Renal and Infectious Outcomes Moayedi, Y., Henricksen, E. J., Lafreniere-Roula, M., Fan, C. S., Multani, A., Puing, A., Couture-Cosette, A., Quintero, O., Han, J., Feng, K. Y., Lee, R., Duclos, S., Lyapin, A., Purewal, S., Subramanian, A., Ross, H. J., Hiesinger, W., Khush, K. K., Teuteberg, J. J. ELSEVIER SCIENCE INC. 2020: S274–S275